Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Bioorg Med Chem Lett ; 21(23): 7155-65, 2011 Dec 01.
Article in English | MEDLINE | ID: mdl-22014550

ABSTRACT

Discovery of a new class of DFG-out p38α kinase inhibitors with no hinge interaction is described. A computationally assisted, virtual fragment-based drug design (vFBDD) platform was utilized to identify novel non-aromatic fragments which make productive hydrogen bond interactions with Arg 70 on the αC-helix. Molecules incorporating these fragments were found to be potent inhibitors of p38 kinase. X-ray co-crystal structures confirmed the predicted binding modes. A lead compound was identified as a potent (p38α IC(50)=22 nM) and highly selective (≥ 150-fold against 150 kinase panel) DFG-out p38 kinase inhibitor.


Subject(s)
Computer Simulation , Drug Discovery , Enzyme Inhibitors , Oligopeptides/chemistry , Thiophenes , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , Adenosine Triphosphate/chemistry , Animals , Crystallography, X-Ray , Dexamethasone/pharmacology , Enzyme Activation/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Humans , Inhibitory Concentration 50 , Mice , Models, Molecular , Molecular Structure , Rats , Thiophenes/chemical synthesis , Thiophenes/chemistry , Thiophenes/pharmacology
2.
ACS Med Chem Lett ; 10(7): 1033-1038, 2019 Jul 11.
Article in English | MEDLINE | ID: mdl-31312404

ABSTRACT

Protein arginine methyltransferase 5 (PRMT5) is known to symmetrically dimethylate numerous cytosolic and nuclear proteins that are involved in a variety of cellular processes. Recent findings have revealed its potential as a cancer therapeutic target. PRMT5 possesses a cysteine (C449) in the active site, unique to PRMT5. Therefore, covalent PRMT5 inhibition is an attractive chemical approach. Herein, we report an exciting discovery of a series of novel hemiaminals that under physiological conditions can be converted to aldehydes and react with C449 to form covalent adducts, which presumably undergo an unprecedented elimination to form the thiol-vinyl ethers, as indicated by electron density in the co-crystal structure of the PRMT5/MEP50 complex.

3.
J Med Chem ; 54(1): 179-200, 2011 Jan 13.
Article in English | MEDLINE | ID: mdl-21126027

ABSTRACT

The synthesis and optimization of a series of orally bioavailable 1-(1H-indol-4-yl)-3,5-disubstituted benzene analogues as antimitotic agents are described. A functionalized dibromobenzene intermediate was used as a key scaffold, which when modified by sequential Suzuki coupling and Buchwald-Hartwig amination provided a flexible entry to 1,3,5-trisubstituted phenyl compounds. A 1H-indol-4-yl moiety at the 1-position was determined to be a critical feature for optimal potency. The compounds have been shown to induce cell cycle arrest at the G2/M phase and demonstrate efficacy in both cell viability and cell proliferation assays. The primary site of action for these agents is revealed by their colchicine competitive inhibition of tubulin polymerization, and a computational model has been developed for the association of these compounds to tubulin. An optimized lead LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model.


Subject(s)
Indoles/chemical synthesis , Isonicotinic Acids/chemical synthesis , Sulfonamides/chemical synthesis , Tubulin Modulators/chemical synthesis , Animals , Biological Availability , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Colchicine/chemistry , Drug Screening Assays, Antitumor , G2 Phase , Humans , Indoles/chemistry , Indoles/pharmacology , Isonicotinic Acids/chemistry , Isonicotinic Acids/pharmacology , Mice , Mice, Nude , Models, Molecular , Neoplasm Transplantation , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , Sulfonamides/chemistry , Sulfonamides/pharmacology , Transplantation, Heterologous , Tubulin/chemistry , Tubulin Modulators/chemistry , Tubulin Modulators/pharmacology
4.
Bioorg Med Chem Lett ; 15(23): 5274-9, 2005 Dec 01.
Article in English | MEDLINE | ID: mdl-16169718

ABSTRACT

Two new classes of diphenylether inhibitors of p38alpha MAP kinase are described. Both chemical classes are based on a common diphenylether core that is identified by simulated fragment annealing as one of the most favored chemotypes within a prominent hydrophobic pocket of the p38alpha ATP-binding site. In the fully elaborated molecules, the diphenylether moiety acts as an anchor occupying the deep pocket, while polar extensions make specific interactions with either the adenine binding site or the phosphate binding site of ATP. The synthesis, crystallographic analysis, and biological activity of these p38alpha inhibitors are discussed.


Subject(s)
Biphenyl Compounds/chemistry , Biphenyl Compounds/pharmacology , Ethers/chemistry , Ethers/pharmacology , Mitogen-Activated Protein Kinase 14/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Crystallography, X-Ray , Humans , Models, Molecular , Molecular Structure , Protein Binding , Protein Kinase Inhibitors/classification , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL